2.png)
Synpromics Ltd, a leading synthetic promoter and gene control company, has announced a research collaboration with GE Healthcare to jointly develop customised synthetic promoters optimised for GE Healthcare’s proprietary biopharmaceutical manufacturing platform.
Synpromics will develop a complex bar-coded library of synthetic promoters, using its proprietary PromPT platform, for extensive screening in GE Healthcare’s Chinese Hamster Ovary (CHO) - based expression system. The resulting characterised promoter toolbox is anticipated to have broad applicability for increasing the yield of a range of biopharmaceuticals, including proteins difficult to manufacture. GE Healthcare is paying an upfront technology access fee and will have the rights to commercialise the improved platform.
Dr David Venables, CEO of Synpromics, commented, “We are delighted to be working with GE Healthcare, a world leading technology innovator to develop and commercialise our novel synthetic promoter platform. We believe our synthetic promoters will provide a much more efficient production system and we’re aiming to help GE Healthcare boost efficiency for its biopharma customers.”
“We are happy to be able to collaborate with Synpromics on developing enhanced tools for manufacturing biologics and thereby support our customers in their production efforts”, said Morgan Norris, GM, Upstream and Cell Culture for GE Healthcare’s Life Sciences business.
Synpromics, ge healthcare ink research pact, jointly develop novel synthetic promoter platform
21.png)
